"Hematinics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
| Descriptor ID |
D006397
|
| MeSH Number(s) |
D27.505.954.502.543
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hematinics".
Below are MeSH descriptors whose meaning is more specific than "Hematinics".
This graph shows the total number of publications written about "Hematinics" by people in this website by year, and whether "Hematinics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematinics" by people in Profiles.
-
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clin Exp Nephrol. 2023 Aug; 27(8):651-659.
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
-
Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):426-433.
-
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2021 01; 32(1):211-222.
-
Factors affecting employment at initiation of dialysis. Clin J Am Soc Nephrol. 2011 Mar; 6(3):489-96.
-
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9.
-
Hemoglobin variability in chronic kidney disease: a cross-sectional study. Am J Med Sci. 2009 May; 337(5):340-3.
-
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 2008 Oct; 3(10):1159-65.
-
Anemia and the frail elderly. Semin Hematol. 2008 Oct; 45(4):261-6.
-
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res. 2008 May-Jun; 28(3B):1767-71.